Navigation Links
Harvard researchers, pharma experts offer recommendations to expand access to clinical trial data
Date:10/22/2013

Boston, MA A new report by researchers from Harvard University and others in a working group convened by the Multi-Regional Clinical Trials Center (MRCT) at Harvard proposes recommendations for addressing a problem that has vexed drug regulators: how to expand public access to data from clinical trials while protecting patients' privacy and weighing pharmaceutical companies' business interests. Recently, the European Medicines Agency (EMA) announced it will provide public access to participant-level data submitted in applications for marketing approval in Europe, prompting questions about whether the U.S. Food and Drug Administration should follow suit. Data releases by the EMA have spurred litigation by drug companies and heated debate about whether clinical trial data should be protected as proprietary information or widely shared.

The report, published online October 21, 2013 in The New England Journal of Medicine, was released to coincide with the first meeting of the Institute of Medicine's Committee on Strategies for Responsible Sharing of Clinical Trial Data on October 23. The Institute of Medicine convened the committee on an accelerated timetable to develop a framework for expanded public access to clinical trial data. An initial report is expected in January 2014.

"Our experiences with Vioxx, Avandia, and other widely prescribed drugs that were revealed to have serious safety risks show how important it is to give independent scientists access to clinical trial data," said Michelle Mello, professor of law and public health at the Harvard School of Public Health and lead author of the report. "The question is, how can we achieve the powerful public health benefits of data sharing while protecting research participants' privacy, avoiding 'junk science,' and minimizing burdens on trial sponsors?"

According to the authors, expanding access to participant-level data could both serve as a check on trial sponsors' character
'/>"/>

Contact: Marge Dwyer
mhdwyer@hsph.harvard.edu
617-432-8416
Harvard School of Public Health
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Genia Technologies, Columbia University, and Harvard University Awarded $5.25 Million Grant from NIH to Accelerate the Development of NanoTag DNA Sequencing Technology
2. Jeffrey Epstein, Science Financier, Changes the Course of Evolution at Harvard
3. Director of Proteomics at the Broad Institute of MIT and Harvard, Steven Carr, to Deliver Pittcon 2014 Wallace H. Coulter Plenary Lecture
4. Life Technologies Signs License and Collaborative Stem Cell Research Agreement with Harvard University
5. Harvard Wyss Institutes Lung-on-a-Chip wins prize for potentially reducing need for animal testing
6. Harvards Wyss Institute team creates versatile 3d nanostructures using DNA bricks
7. Harvards Wyss Institute models a human disease in an organ-on-a-chip
8. UMass Amherst, Harvard experts say better systems needed for medical device cybersecurity
9. Harvards Wyss Institute creates living human gut-on-a-chip
10. Harvards Wyss Institute develops DNA nanorobot to trigger targeted therapeutic responses
11. Niels Bohr Institute gets top researcher from Harvard
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)...  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... Chief Executive Officer of Neurocrine Biosciences, will be presenting ... The live presentation takes place on Tuesday, ... will be webcast and may be accessed on the ... Listeners are encouraged to visit the website approximately 5 ...
(Date:3/3/2015)... , March 3, 2015  Regenicin, Inc. (OTC ... specializing in the development of and commercialization of regenerative ... and organs, announced today that it has received the ... Amarantus Bioscience Holdings, Inc. (OTC Bulletin Board: ... Agreement, Amarantus made the final payments due to Regenicin ...
(Date:3/3/2015)... March 3, 2015  Thingee Corporation, a software development ... a presentation entitled, "Technology Adoption: Making Reps, Lives Easier" ... Innovations and Technology ,  in Deerfield Beach, ... 13, 2015. Audiences looking to learn how technology can ... to be in the audience for the Thingee presentation. ...
(Date:3/3/2015)... Switzerland (PRWEB) March 03, 2015 ... for drug discovery and life science research, today ... Biologics (TM) enterprise platform for use at Pfizer ... and Europe. Genedata is supporting Pfizer’s global deployment ... Technologies (GBT), Centers for Therapeutic Innovation (CTI), and ...
Breaking Biology Technology:Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3Thingee to present at 11th Annual Synergistix Users Conference 2Genedata Biologics Licensed by Pfizer Inc. 2Genedata Biologics Licensed by Pfizer Inc. 3
... R-Tech Ueno, Ltd. announced on July 29 after discussing its R&D ... the day and determined the R&D items as follows. , ... the ophthalmologic & dermatological fields that are its priority and exclusive ... , 1. Development code UF-021 (eye diseases) , ...
... , , SAN DIEGO, July 30 ... the protocol for the Company,s Phase II trial of ANA598 in combination ... the protocol has been received from the United States Food and Drug ... several weeks. , , In the Phase II study, ...
... , , SEATTLE, July 30 Trubion ... to issue earnings results for its second quarter and six months ended ... The company,s earnings conference call will take place Aug. 6, 2009 at ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO ) , , The ...
Cached Biology Technology:R-Tech Ueno Notifies R&D Items 2R-Tech Ueno Notifies R&D Items 3Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 2Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 3Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 4Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 5Trubion Announces Dates for Second Quarter and First Half 2009 Earnings Conference Call 2
(Date:2/12/2015)... OXFORD, Conn. , Feb. 12, 2015 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... it has filed provisional patent 62/113114 for ... MULTIPLE DEVICES. The patent further establishes NXT-ID,s ... to its intellectual property portfolio the ability for multiple ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America ... methods for carbon nanotube (CNT) macrostructures, including sheets, yarns ... Dallas (UTD). Leveraging the vast industrial resources ... Tokyo, Japan , Lintec of America is forming ... Richardson, TX , focusing on scaling up the ...
(Date:2/5/2015)... DIEGO , Jan. 26, 2015   Epic Sciences ... of cancer, today announced that Murali Prahalad , Ph.D., ... Personalized Medicine World Conference (PMWC) 2015: Silicon Valley, which ... Mountain View, Calif. on January 26-28, 2015. ... "CTCs Come of Age as Biomarkers." Last year, Epic Sciences ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2
... flowers have evolved particular colours, shapes and scents ... using artificial flowers and high-speed video, researchers have ... hummingbirds and the flowers they pollinate. The study, ... Functional Ecology , is the first to measure ...
... grey seal mums adopt risky tactics when it comes to the ... a real advantage, according to scientists. Researchers from Durham University, ... colonies in Scotland, found that some seal mothers are flexible in ... their actions, whilst other play it safe and steady. ...
... Calif.) When your neighbor asks to borrow a cup of ... of the give and take that characterize your longstanding relationship? Or ... of sugar you borrowed last week, or may need to borrow ... anthropology at UC Santa Barbara, and a junior research fellow at ...
Cached Biology News:High-speed video and artificial flowers shed light on mysteries of hummingbird-pollinated flowers 2Seals gamble with their pups' futures 2Seals gamble with their pups' futures 3UCSB anthropologist studies reciprocity among chimpanzees and bonobos 2UCSB anthropologist studies reciprocity among chimpanzees and bonobos 3
amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 2...
IKKbeta/IKK-2 Polyclonal Antibody 100 ug affinity purified rabbit polyclonal antibody. Reacts with human. Tested in Western blotting....
... RACE (rapid amplification of cDNA ends) technique ... 5' and 3' cDNA ends. The GeneRacer ... Transcriptase (RT) for improved amplification of the ... mRNA. The RNase H portion of SuperScript ...
activating transcription factor 4 (tax-responsive enhancer element B67),...
Biology Products: